Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CERT 
Certara Inc (CERT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: CERT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $15.78
1 Year Target Price $15.78
| 4 | Strong Buy |
| 1 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.21% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.85B USD | Price to earnings Ratio - | 1Y Target Price 15.78 |
Price to earnings Ratio - | 1Y Target Price 15.78 | ||
Volume (30-day avg) 11 | Beta 1.45 | 52 Weeks Range 8.63 - 16.93 | Updated Date 07/9/2025 |
52 Weeks Range 8.63 - 16.93 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.02 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.67% | Operating Margin (TTM) 7.19% |
Management Effectiveness
Return on Assets (TTM) 1.12% | Return on Equity (TTM) -0.25% |
Valuation
Trailing PE - | Forward PE 24.51 | Enterprise Value 1975011639 | Price to Sales(TTM) 4.69 |
Enterprise Value 1975011639 | Price to Sales(TTM) 4.69 | ||
Enterprise Value to Revenue 5.01 | Enterprise Value to EBITDA 23.63 | Shares Outstanding 162234000 | Shares Floating 121837605 |
Shares Outstanding 162234000 | Shares Floating 121837605 | ||
Percent Insiders 2.48 | Percent Institutions 100.9 |
Upturn AI SWOT
Certara Inc
Company Overview
History and Background
Certara, Inc. was founded in 2008 through the merger of several leading biosimulation companies. It focuses on biosimulation software and services to improve drug development and regulatory science. The company went public in December 2020.
Core Business Areas
- Model-Informed Drug Development (MIDD): This segment provides software and services that use biosimulation and data analytics to optimize drug development processes, predict clinical trial outcomes, and support regulatory submissions.
- Integrated Drug Development: This segment offers a suite of services to help biotech, pharma and biosimilar companies de-risk their investment decisions and maximize product opportunities.
Leadership and Structure
Certara is led by CEO William F. Feehery. The organizational structure includes various functional departments such as R&D, sales, marketing, finance, and operations.
Top Products and Market Share
Key Offerings
- Simcyp: A physiologically based pharmacokinetic (PBPK) modeling and simulation platform used to predict drug behavior in different populations and inform clinical trial design. Competitors include Open Systems Pharmacology (NONMEM, Monolix) and academic institutions. Market share is estimated to be significant within the PBPK modeling market.
- Phoenix: A pharmacokinetic and pharmacodynamic (PK/PD) modeling and analysis software platform used for data analysis, non-compartmental analysis, and population PK/PD modeling. Competitors include NONMEM and R. Market share is also considerable within its target market.
Market Dynamics
Industry Overview
The biopharmaceutical industry faces increasing pressures to reduce drug development costs and timelines. Regulatory agencies are also encouraging the use of model-informed drug development (MIDD) approaches. The market for biosimulation software and services is growing.
Positioning
Certara is a leading provider of biosimulation software and services. Its competitive advantages include a comprehensive product portfolio, deep domain expertise, and a strong track record of successful regulatory submissions.
Total Addressable Market (TAM)
The total addressable market for biosimulation is estimated to be several billion USD. Certara is well-positioned to capture a significant share of this market given its extensive capabilities.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Comprehensive product portfolio
- Deep domain expertise
- Global presence
- Long-standing relationships with regulatory agencies
Weaknesses
- Dependence on the biopharmaceutical industry
- Relatively high price point
- Complexity of software requires specialized training
Opportunities
- Increasing adoption of MIDD by regulatory agencies
- Expansion into new therapeutic areas
- Growth in emerging markets
- Integration of artificial intelligence and machine learning into biosimulation
- Increasing use of real world evidence (RWE) in drug development
Threats
- Competition from other biosimulation vendors
- Economic downturn affecting biopharmaceutical R&D spending
- Regulatory changes
- Open-source alternatives
- Data privacy and security concerns
Competitors and Market Share
Key Competitors
- Certara(CERT)
- Simulations Plus (SLP)
- Dassault Systemes (DSY.PA)
Competitive Landscape
Certara has advantages in its comprehensive product portfolio and deep domain expertise. Competitors may have strengths in specific areas such as specialized software or broader life sciences solutions.
Major Acquisitions
Pinnacle 21
- Year: 2020
- Acquisition Price (USD millions): 200
- Strategic Rationale: Expanded its data analysis and regulatory submission capabilities
Growth Trajectory and Initiatives
Historical Growth: Certara's historical growth has been driven by increasing demand for biosimulation software and services. Growth will be filled in with the past year's revenue growth from latest reports.
Future Projections: Future growth is projected to be driven by continued adoption of MIDD, expansion into new markets, and strategic acquisitions. This growth has been discussed at various conference calls and will be filled in when data is available.
Recent Initiatives: Recent strategic initiatives include acquisitions of companies to expand product offerings, partnerships with biopharmaceutical companies, and investments in R&D.
Summary
Certara is a key player in biosimulation with a strong product portfolio and expertise, benefiting from increased MIDD adoption. While facing competition and industry dependence, it has growth opportunities through market expansion and AI integration. Certara's strategic acquisitions and collaborations further strengthen its position within the biopharmaceutical industry. The company must be vigilant against economic changes and evolving regulatory landscapes to maintain momentum.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Certara Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is based on available information and estimates. Actual results may vary. This is not financial advice. Please consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Certara Inc
Exchange NASDAQ | Headquaters Radnor, PA, United States | ||
IPO Launch date 2020-12-11 | CEO & Director Dr. William F. Feehery Ph.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 1487 | Website https://www.certara.com |
Full time employees 1487 | Website https://www.certara.com | ||
Certara, Inc., together with its subsidiaries, provides technology-enabled services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. The company also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix Hosted, which offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration, which supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform for drug discovery teams and their external collaborators; Certara D360 software, a scientific informatics system for small molecule and biologics discovery research; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and assembles regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara I
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.